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MediatorSteroid receptor coactivator 2 (SRC-2) is a coactivator that regulates nuclear receptor activity. We previously
reported that SRC-2 protein is degraded through the action of cAMP-dependent protein kinase A (PKA) and
cAMP response element binding protein (CREB). In the study presented here, we aimed to identify proteins
that interact with and thereby regulate SRC-2. We isolated cyclin C (CCNC) as an interacting partner with the
SRC-2 degradation domain aa 347-758 in a yeast two-hybrid assay and conﬁrmed direct interaction in an
in vitro assay. The protein level of SRC-2 was increased with CCNC overexpression in COS-1 cells and decreased
with CCNC silencing in COS-1 and MCF-7 cells. In a pulse-chase assay, we further show that silencing of CCNC
resulted in a different SRC-2 degradation pattern during the ﬁrst 6 h after the pulse. Finally, we provide evidence
that CCNC regulates expression of cell cycle genes upregulated by SRC-2. In conclusion, our results suggest that
CCNC temporarily protects SRC-2 against degradation and this event is involved in the transcriptional regulation
of SRC-2 cell cycle target genes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The activity of nuclear receptors (NRs) depends not only on binding
of their ligands (e.g. steroid hormones, metabolites and bile acids), but
also on the presence of coactivators and corepressors. The steroid
receptor coactivator (SRC) family consists of three members: SRC-1,Bcl-2, apoptosis regulatorB-cell
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SRC-2 (also known as NCoA2, TIF2 or mouse homologue GRIP1) is
involved in many important biological processes such as mammary
morphogenesis and fertility [4] and bone metabolism [5]. Moreover,
SRC-2 mediates hepatic glucose release during fasting and regulation
of bile acid secretion [6,7], whereas absence of SRC-2 has been shown
to protect against high-fat induced obesity [8]. It has also been shown
that SRC-2 may have an oncogenic function in prostate cancer [9] as
well as in breast cancer tissue, where its expression correlates with
the expression of ERα [10]. During tumorigenesis, SRC-2 is initially
increased in intraductal carcinomas compared to normal mammary
glands. However, further tumor development is associated with a
decrease in SRC-2 in invasive ductal carcinomas [11]. Moreover, cellular
studies have shown that SRC-2 is functionally distinct from the other
SRC members, as we have previously demonstrated stable knockdown
of SRC-2 induced proliferation in ER-positiveMCF-7 cells [12]. Addition-
ally, unlike SRC-1 and SRC-3, SRC-2 can both coactivate and corepress
ERα transcriptional activity [13].
The activity of SRC-2 depends closely on ubiquitin/proteasome-
mediated protein turnover [14]. We previously found that SRC-2
coactivation of ERα-mediated transcription and SRC-2 protein level
are tightly regulated by cAMP-dependent protein kinase (PKA) in
two distinct ways. While short-term PKA activation increases the
recruitment of SRC-2 to ERα and thereby promotes transcription
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through the ubiquitin/proteasome pathway [15,16]. Furthermore, we
have found that SRC-2 degradation involves cAMP response element
binding protein (CREB) and two SRC-2 protein domains – aa 347-758
and aa 1121-1462 [17]. A scheme of SRC-2 protein structure and its
domain aa 347-758 is shown in Fig. 1A.
Cyclins and cyclin-dependent kinases (CDKs) accumulate during
tumorigenesis, thereby promoting the cell cycle, bypassing the control
points for DNA integrity and diminishing apoptosis in mutated cells.
Cyclins, in a large majority of cases, act through their associated CDKs
and are often involved in transcriptional regulation. The function of
cyclin C (CCNC), in contrast to most other cyclins, remains largely
unknown. Hepatoma cell lines show CCNC upregulation, followed by
increased proliferation, and a recent study points to CCNC as a main
cell cycle effector of Wnt/β-catenin pathway in the early development
of hepatoma [18,19]. Furthermore, CCNC is overexpressed in 88%
colon cancers and 82.6% of breast cancers, and is found to correlate
with increased proliferation in breast cancer, underlining its important
function in tumorigenesis [20–22]. CCNC interacts with several cyclin-
dependent kinases (CDKs), two of which confer its function in
two different ways [23]. On one hand, CDK3 involves CCNC into cell
cycle regulation, where CCNC stimulates re-entry into the cell cycle
(G0/G1 transition), and it has been noted that this re-entry can occur
directly into the G1/S transition point [24–26]. On the other hand,
CCNC associates with CDK8 into a CDK module (SRB complex in yeast)
as part of the Mediator and is involved in transcriptional regulation
[27,28]. Although CDK module was ﬁrst reported to repress transcrip-
tion in vitro by phosphorylation of the CTD tail of RNApolII, further
in vivo evidence shows the module has in fact a stimulatory effect on
transcription in colon cancer [29,30]. CDK module is found in complex
with ERα and can further activate transcription by modifying histones
[31,32].
Unlike other cyclins, CCNC is highly expressed throughout the entire
cell cycle and its protein level peaks merely two-fold just prior to G1/S
transition, when it binds to CDK3 [33]. Endogenous CCNC is very stable,
despite the fact that it is a cyclin (half-life of 4 h), and is stabilized by
binding to and being phosphorylated by its CDKs [34]. CCNC protein
structure is highly conserved and is comprised of two Cyclin repeats,
characteristic for cyclins (Fig. 1B). In addition to each repeat having
ﬁve helices, the N-terminus contains a highly mobile helix HN and the
protein lacks C-terminus helices [35]. CCNC exists in two protein
isoforms (a and b) due to alternative splicing from a downstream tran-
scriptional start codon. The two isoforms are differentially expressed in
various tissues, but no functional distinction has been made between
the two isoforms [36].
The aimof this studywas to identify proteinswhich interactwith the
SRC-2 degradation domain aa 347-758 and study their involvement in
regulation of SRC-2.Fig. 1. Secondary structure of SRC-2 and CCNC. (A) Functional domains of full-length SRC-2, in
assay. Basic helix-loop-helix domain (bHLH), Per-Arnt-Simdomain (PAS) and the nuclear recep
and AD2). (B) Secondary structure of CCNC comprises a highly mobile N-terminal helix (HN), f
arise from an alternative transcriptional start site. Minimum element of CCNC, binding to SRC-2. Materials and methods
2.1. Expression plasmid constructs, siRNA and chemicals
The expression of 6His-SRC-2, HA-SRC-2 [17,37] and Flag-CCNC [38]
has been previously described. For knockdown experiments we tested
several target-speciﬁc siRNA molecules in various combinations and
concentrations and settled on a combination of two siRNAs targeting
CCNC at starting mRNA positions 476 and 755. This combination pro-
duced no effect on mRNA and protein level of several tested genes.
The target-speciﬁc and non-speciﬁc control (NSC) siRNA were
custom-ordered (Sigma Aldrich, St. Louis, MO, USA) and are described
elsewhere [39]. Cycloheximide (CHX) was purchased from Sigma
(C7698) and resuspended in sterile water.
2.2. Yeast two-hybrid assay
The assay was performed by Hybrigenics, S.A, Paris, France (www.
hybrigenics.com). Brieﬂy, the cDNA coding for the aa 347-758 fragment
of human SRC-2 was cloned as a C-terminal fusion to the DNA-binding
domain of LexA in pB27 vector (N-LexA-SRC-2 347-758-C). The con-
struct was introduced into yeast strains as bait to screen high-
complexity random-primed cDNA library (prey library) of human em-
bryonic stem cell, as previously described [40]. After selection on medi-
um lacking leucine, tryptophane and histidine, positive clones were
isolated and the corresponding prey fragments were identiﬁed using
GenBankDatabase and bioinformatics tools (BLASTN). Predicted biolog-
ical score (PBS) was calculated to assess the reliability of each
interaction.
2.3. In vitro protein–protein interaction assay
Expression of recombinant 6His-SRC-2 protein in the insect cell line
Sf21 and protein puriﬁcation by afﬁnity chromatography were previ-
ously described [17]. Two protein isoforms of CCNC were expressed
in vitro from the same expression plasmid (pcDNA3.1-Flag-CCNC),
using TnT® T7 Coupled Reticulocyte Lysate System (Promega, Madison,
WI, USA) in presence of [35S]methionine (Perkin Elmer, Waltham, MA,
USA). 1.6 μg of 6His-SRC-2, 6His-peptide (Covance, Princeton, NJ,
USA), 6His-collagen COL4A3 and 6His-β-actin (Abcam, Cambridge,
UK) were individually incubated with 15 μl [35S]methionine-labeled
CCNC protein as is described elsewhere [17,41].
2.4. Cell cultures, transfections and harvesting
COS-1 cells were transfected to overexpress proteins, using
SuperFect Transfection Reagent (Qiagen, Valencia, CA, USA) as previ-
ously described [16]. For knockdown of CCNC, a total of 36 nM andaddition to the SRC-2 domain aa 347-758, which was used as bait in the yeast two-hybrid
tor interaction domain (NID) are indicated, while ADdenotes two activation domains (AD1
ollowed by two Cyclin repeats, each containing ﬁve helices (H1–H5). Two CCNC isoforms
2, is depicted as a grey frame. Adapted from Hoeppner et al. [35].
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using Lipofectamine Transfection Reagent (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s recommendations. Simultaneous
co-transfection of plasmid DNA and siRNA into COS-1 cells was
performed in 6-well plates. The total DNA amount was maintained
constant for all wells within an experiment, by complementing with
appropriate empty vectors.
Cells were harvested for both RT-qPCR and Western blot analyses
48 h posttransfection. Biological parallels were retained for RT-qPCR
analysis, while in certain experiments they were pooled for Western
blot analysis. For RT-qPCR analyses, cell pellets were lysed in RLT buffer
(Qiagen, Valencia, CA, USA), whereas for protein analyses, a Western
blot lysis buffer was used as previously described [16].
2.5. RNA isolation, reverse transcription and quantitative real-time PCR
Total RNA was isolated from cells using RNeasy Mini kit (Qiagen,
Valencia, CA, USA). cDNA was synthesized from 1 μg RNA per reaction,
using High Capacity cDNA Reverse Transcription Kit with RNase inhibi-
tors (Applied Biosystems, Foster City, CA, USA). Quantitative real-time
PCR was performed using LightCycler 480 Probes Master (Roche,
Penzberg, Germany). Primer sequences (Sigma Aldrich, St. Louis, MO,
USA) with matching probe numbers (Roche, Penzberg, Germany) are
shown in Supplemental Table 1. TBP mRNA expression was assessed
using UPL Human TBP Gene Assay (Roche, Penzberg, Germany). The
mRNA level of all target genes was determined relative to TBP.
2.6. Western blotting and immunostaining
Denatured protein samples were loaded onto 4-20% SDS-PAGE gels
(BioRad, Hercules, CA, USA). Western blot was performed using the
Trans-Blot Turbo Transfer System (BioRad). HA-SRC-2 protein was
detected using rat monoclonal anti-HA-horseradish peroxidase anti-
body (clone 3 F10, Roche, Penzberg, Germany). SRC-2 was detected by
mouse monoclonal anti-TIF2 antibody (610985, BD Biosciences
Pharmingen, East Rutherford, NJ, USA) and goat anti-mouse antibody
(554002, BD Biosciences Pharmingen). CCNC was detected using rabbit
polyclonal anti-CCNC (ab-85927, Abcam, Cambridge, UK), followed by
goat anti-rabbit antibody (31460, Pierce Thermo Scientiﬁc, Waltham,
MA, USA). Reference protein GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) was detected by applying primary mouse monoclonal
anti-GAPDH (C5, MAB 374, Merck Millipore, Billerica, MA, USA) and
secondary donkey anti-mouse antibody (sc-2096, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA).
Membranes were blocked in 5% skimmed milk-PBS-Tween (0.1%)
for 1 h, with consequent step-wise washing in PBS-Tween. Detection
of blots was performed applying SuperSignal West Femto Maximum
Sensitivity Substrate (Pierce Thermo Scientiﬁc, Waltham, MA, USA)
and visualized on ChemiDoc XRS System (BioRad, Hercules, CA, USA),
using the Live Acquire option.
2.7. Pulse-chase
Pulse-chase analysis and consequent immunoprecipitation were
performed as previously described [16]. Brieﬂy, COS-1 cells, were
depleted of methionine for 1 h and then labeled with [35S]methionine
(PerkinElmer, Waltham, MA, USA) for 1.5 h. Prior to immunoprecipita-
tion with anti-GRIP1 antibody (Pierce, MA5-11553, Waltham, MA,
USA), the DNA was sheared by passing the sample through a 21 gauge
needle 5 times. Samples were resolved on SDS-gel and detected by
autoradiography.
2.8. Protein quantitation
Quantitation of proteins in a solution was performed using the
Lowry-based DC Protein Assay (BioRad, Hercules, CA, USA). Westernblot quantitation was implemented on the last raw image before
overexposure of the target protein, using integrated software
(QuantityOne) with Local Background option. Target proteins were
related to GAPDH as reference. Quantitation of radioactive signal was
performed using adjoining software MultiGauge (Fujiﬁlm, Tokyo,
Japan). Lanes were proﬁled tightly on raw images (lane width was
constant), after which bands were manually deﬁned by cutting out
the proﬁle peaks from the background. No additional background
corrections were made, in line with ﬁndings by Gassmann et al. [42].
For the in vitro interaction assays, the results between gelswere normal-
ized to input, and for the pulse-chase experiments, the results were
related to time point zero.2.9. Statistical and bioinformatic analysis
Outlier determination, statistical signiﬁcance and correlation
analysis were calculated using IBM SPSS Statistics 21 software. In
determining statistical signiﬁcance, we applied a two-tailed indepen-
dent-sample t-test and did not assume equal variances between two
distributions. In bivariate correlation analysis, we used Spearman’s
rank-order correlation. Two CCNC protein isoforms were aligned using
ClustalW web tool. Secondary structure predictions of two CCNC
isoforms were performed using Jpred3 tool with N95% similarity
between two isoforms.3. Results
3.1. SRC-2 interacts directly with CCNC
We previously showed that SRC-2 interacts with CREB and that this
interaction is required for PKA-dependent degradation of SRC-2 [16,17].
The SRC-2 protein domain aa 347-758 (Fig. 1A)was identiﬁed as neces-
sary for this degradation process. Therefore, we used this protein
domain as bait in a yeast two-hybrid screening to identify proteins,
whichmay interact with SRC-2. The assay screened a human embryonic
stem cell cDNA library and interactionwith CCNCwas identiﬁed as very
reliable (PBS categories A-C) (Supplemental Table 2).
To ascertain that a direct interaction occurs between CCNC and SRC-
2, we performed an in vitroprotein–protein interaction assay. 6His-SRC-
2 was puriﬁed by afﬁnity chromatography from Sf21 cells. The purity
of selected 6His-SRC-2 protein elution fraction, estimated to be of sufﬁ-
cient quality, is shown in Supplemental Fig. 1. Total protein concentra-
tion of the fraction was approximated as the concentration of 6His-
SRC-2. Full-length CCNC isoform a (molecular weight 33 kDa) showed
slightly less efﬁcient TnT expression than shorter isoform b (23 kDa)
(Fig. 2, upper). Equal amount of 6His-SRC-2, 6His peptide, 6His-
collagen and 6His-beta-actin were taken into separate interaction
reactions with both radio-labeled CCNC isoforms. Five independent
experiments were performed and two CCNC isoforms were separately
quantiﬁed (Fig. 2, lower).
Both CCNC isoforms immunoprecipitatedwith 6His-SRC-2 and seem
to show similar binding afﬁnity as compared to their respective input.
Of note, in the Y2H assay, we observed that theminimum CCNC protein
sequence interacting with SRC-2 pertains to the N-terminal domain up
to and including mRNA nucleotide 582 and corresponds to amino-acid
sequence up to and including residue E98 in full-length CCNC protein.
This N-terminal protein sequence (N-terminal helix and a section
of Cyclin repeat 1) is marked with a grey frame in Fig. 1B. Thus, it
appears that helix 3 (H3) is the only element isoform b shares with
full-length CCNC, which still enables the in vitro interaction with SRC-
2. In conclusion, our Y2H screen, using the previously identiﬁed SRC-2
degradation domain, identiﬁed CCNC as an interacting protein and a
direct interaction between the two proteins was conﬁrmed by an
in vitro assay.
Fig. 2. In vitro protein interaction between SRC-2 andCCNC. Upper: CCNCwas in vitro tran-
scribed and translated into two [35S]methionine-labeled CCNC protein isoforms. [35S]-
CCNC (input) was incubated with 6His-SRC-2 and following negative controls: 6His pep-
tide, 6His-collagen COL4A3, 6His-β-actin and protein buffer. 6His pull-down interaction
complexeswere resolved by SDS-PAGE and [35S]-CCNCwas detected by autoradiography.
Lower: Radioactive signal was quantiﬁed separately for two isoforms. Results presented
were normalized to their relative inputs (grey bar) and represent mean± SD of ﬁve (iso-
form a) and three (isoformb) independent experiments. CCNC interactionwith 6His-SRC-
2 was statistically compared to interactionswith negative controls (6His peptide and pro-
tein buffer). 6His-collagen was quantiﬁed in duplicates. Statistical signiﬁcance was calcu-
lated using the Student t-test (** p ≤ 0.01).
2386 O. Bozickovic et al. / Biochimica et Biophysica Acta 1853 (2015) 2383–23913.2. CCNC regulates SRC-2 protein level
Involvement of the SRC-2 domain aa 347-758 in the interactionwith
CCNC led us to examine how this interaction regulates SRC-2. To this
end, COS-1 cells were co-transfected with an expression vector
encoding HA-SRC-2, together with increasing amounts of plasmid
expressing CCNC (0.5-3 μg). We found that the protein level of HA-
SRC-2 increased with the elevated amount of transfected CCNC
(Fig. 3A) and statistical correlation analysis showed a signiﬁcant strong
positive correlation (r=0.579). In contrast, this increase in transfected
CCNC was not accompanied by a signiﬁcant increase in mRNA level of
either endogenous or exogenous SRC-2 (Fig. 3B). We were not able to
detect elevated amount of CCNC protein (Fig. 3A), possibly due to the
reduced half-life of the exogenously expressed protein (15 min com-
pared to 4 h), as described by others [34]. Despite that, there was a
marked increase of CCNC mRNA level (Fig. 3B). Taken together, the
results suggest that CCNC regulates the protein level of SRC-2.
In order to examine the role of endogenous CCNC in regulation of
SRC-2, we transiently silenced endogenous CCNC in both COS-1 and
MCF-7 cells (Fig. 4). As shown, CCNC was successfully silenced in both
cell lines and the effect was detected at both the mRNA and protein
level. Simultaneously to CCNC knockdown, SRC-2 protein decreased inboth cell lines, without a concomitant reduction on the mRNA level
(MCF-7 cells p = 0.031), even though the basal SRC-2 protein level is
not high in either of the two cell types [17]. Taking together the overex-
pression and knockdown experiments, the results suggest that CCNC
regulates the SRC-2 protein level.
3.3. CCNC regulates the dynamics of SRC-2 protein degradation
To further examine the effect of CCNCon SRC-2 protein level, we ﬁrst
tested how the silencing of CCNC affects overexpressed HA-SRC-2 in
COS-1 cells (Fig. 5). We observed an effect of silencing CCNC on its
mRNA level already 12 h after transfection (data not shown) and this
reduction remained stable 48 h post-transfection (Fig. 5B). Protein
level of CCNC appeared to be reduced 24 h after siRNA transfection,
and this became statistically signiﬁcant after 48 h (Fig. 5A). The change
inHA-SRC-2 protein level appeared visiblewithin 24 h after transfection
with siRNA targeting CCNC and this reached statistical signiﬁcance 48 h
post-transfection (Fig. 5A). ThemRNA expression of overexpressed HA-
SRC-2 showedno change after signiﬁcant CCNC knockdown at 24h after
transfection (Fig. 5B). A slight decrease detected at 48 h is irrelevant for
protein level at the same timepoint, due to the time-delayed effect of
protein synthesis.
Next, we wanted to see how the translation of SRC-2 is regulated by
CCNC.Hence, COS-1 cellswere co-transfectedwithHA-SRC-2 and siRNA
targeting CCNC, followed by treatment with CHX 20 h post-transfection
(Fig. 6). Twenty-eight hours later, the SRC-2 protein level expectedly
decreased with CCNC silencing, as well as with CHX treatment. More
importantly, the decrease of SRC-2 protein level was proportional
with or without CHX treatment, suggesting that CCNC does not have
any impact on the translation of SRC-2.
Finally, we tested if CCNC regulates SRC-2 protein stability and
degradation. For this, COS-1 cells were co-transfected in order to
overexpressHA-SRC-2 and silence CCNC. Twenty-four hours after trans-
fection, the cells were subjected to pulse-chase with [35S]-Methionine.
The initial 24-hour analysis showed a decrease in SRC-2 protein stability
with CCNC silencing 6 h after the radioactive pulse, as compared to the
control (Fig. 7A). The control shows an expected gradual decrease in
SRC-2 protein level, with an average half-life of 10-12 h, as previously
reported [16]. Relative quantiﬁcation indicated a different SRC-2
degradation pattern when CCNC was depleted (Fig. 7B). We performed
additional experiments to determinemore accurately the time-frame in
which the majority of changes on SRC-2 protein level occur, identifying
the 3-6 h period to be critical (Fig. 7C and D). Our results suggest that
CCNC plays a role in stabilizing the SRC-2 protein level.
3.4. CCNC silencing modulates SRC-2-regulated gene expression
The transcriptional coactivator SRC-2 regulates the expression of
many genes involved in different cellular functions [43]. By regulating
the SRC-2 protein level, CCNC may therefore modulate transcription of
SRC-2 target genes, particularly those involved in cell cycle control.
We previously published a data set of SRC-2 target genes in MCF-7
cells with stable knockdown of SRC-2 [12]. Using PANTHER analysis
tool, we isolated a subset of genes within this set, which are involved
in the regulation of cell cycle andmitosis (biological process, geneontol-
ogy terms: cell cycle and mitosis). Therefore, we examined the effect
of CCNC silencing on the expression of selected SRC-2 target genes.
Interestingly, we found that only genes, which showed decreased ex-
pression with SRC-2 depletion, demonstrated a similar expression pat-
tern after CCNC knockdown (Fig. 8). As exceptions,WISP2 expression
was upregulated and there was no change in the expression level
of SEPT3 after CCNC knockdown. Genes previously found to be upregu-
lated by SRC-2 knockdown remained mostly unchanged with CCNC
depletion (Fig. 9). Our results suggests that CCNC has a preference
towards regulating cell cycle genes which are transcriptionally upregu-
lated by SRC-2.
Fig. 3.Effect of CCNC overexpression on SRC-2 protein andmRNA levels. COS-1 cellswere transiently transfectedwith expression plasmids encodingHA-SRC-2 and Flag-CCNC. The amount
of transfected HA-SRC-2 plasmid remained constant (1.0 μg per well), while the amount of Flag-CCNC plasmid ranged between 0.5 and 3.0 μg per well. Cells were harvested 48 h after
transfection. (A) Six biological parallels were analyzed separately by immunoblotting, using anti-TIF2, anti-CCNC and anti-GAPDH antibodies for detection of total SRC-2, CCNC and
GAPDH, respectively. Immunoblotswere quantiﬁed for protein expression using innate BioRad software and represent the averageof two independent experiments. HA-SRC-2was related
to GAPDH and normalized between two experiments to SRC-2 level without CCNC overexpression (grey bar). (B)mRNA expression levels of endogenous SRC-2, overexpressed HA-SRC-2
and total CCNCweremeasured by RT-qPCR. The expression level was determined relative to TBP. The results representmean± SD of six biological replicates and are representative of two
independent experiments. Statistical signiﬁcance was calculated using the Student t-test (* p ≤ 0.05; ** p ≤ 0.01).
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Accumulating evidence shows the importance of SRCs on various
cellular functions. Here we report that SRC-2 interacts with the cell
cycle protein CCNC. Interestingly, we found that the protein level of
SRC-2 increased with the overexpression of CCNC, and similarly, the
depletion of CCNC resulted in reduced level of SRC-2 protein. Our data
suggest that CCNC does not affect the translation of SRC-2. Pulse-chase
experiments revealed a difference in SRC-2 protein degradation after
CCNC depletion, compared to the non-speciﬁc control. Therefore, the
results suggest that CCNC has a role in stabilizing the level of SRC-2
protein.Fig. 4. Effect of CCNC silencing on endogenous SRC-2 protein and mRNA levels in COS-1 and M
either non-targeting control siRNA (NSC) or the combination of two CCNC-speciﬁc siRNAmolec
ed 48 h post-transfection, as biological triplicates for mRNA analysis and pooled triplicates for
ological parallels and are representative of the independent experiments. (B andD)Todetermin
by immunoblotting, using antibodies against endogenous SRC-2 and CCNC, respectively. StatistiPreviously, we reported that an importantmode of regulating SRC-2
abundance and activity is through its ubiquitin-proteasome-mediated
degradation [16]. Coactivator degradation and their transcriptional
activity are interdependent, as protein degradation is necessary for
repeated transcriptional activation [44]. The critical importance of
degradation process in regulating coactivator activity is further illus-
trated by SRC-3, where a coordinated action of phosphorylation,
polyubiquitination and degradation promotes further cycles of tran-
scriptional activation [45]. In this study, we determined the expression
level of a subset of cell cycle genes known to be either up- or down-
regulated by SRC-2 knockdown in MCF-7 cells [12]. Interestingly,
genes known to be downregulated after SRC-2 depletion were alsoCF-7 cells. COS-1 (A and B) and MCF-7 (C and D) cells were transfected in triplicates with
ules in two (COS-1) or three (MCF-7) independent experiments. Cell lysateswere harvest-
protein analysis. (A and C) Gene expression data are presented as mean ± SD of three bi-
e protein levels, three (COS-1) or six (MCF-7) biological parallelswerepooled and analyzed
cal signiﬁcance was calculated using the Student t-test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).
Fig. 5. Effect of CCNC silencing on overexpressed HA-SRC-2. COS-1 cells were co-
transfected in triplicates in order to overexpress HA-SRC-2, with simultaneous silencing
of endogenous CCNC. Samples were harvested 24 and 48 h post-transfection. The results
represent mean ± SD of three biological replicates. (A) We used anti-HA antibody to de-
tect overexpressed HA-SRC-2, while anti-CCNC and anti-GAPDH antibodies were used to
detect total CCNC and GAPDH protein, respectively. B. mRNA expression levels of
overexpressed HA-SRC-2 and total CCNC were determined by RT-qPCR. Statistical
signiﬁcance was calculated using the Student t-test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).
Fig. 6. CCNC has no effect on SRC-2 translation. COS-1 cells were co-transfected in order to
overexpress HA-SRC-2 and silence endogenous CCNC. Twenty hours post-transfection,
cellswere treatedwith either 5 or 10 μMCHX andwereharvested 28 h later. Immunoblot-
ting was performed using anti-HA and anti-CCNC antibodies. Quantitation results (lower)
representmean± SD of three biological replicates and are representative of two indepen-
dent experiments.
2388 O. Bozickovic et al. / Biochimica et Biophysica Acta 1853 (2015) 2383–2391downregulated after CCNC depletion. Even though CCNCdepletion does
not reduce expression of SRC-2-target genes by more than 40% of their
basal mRNA level, it should be noted that thesemodest changes in geneexpressionmay be caused by an indirect effect of CCNCon SRC-2 protein
level. In contrast, genes shown to be upregulated after SRC-2 knock-
down, retained the same level of expression after CCNC depletion.
Therefore, it seems that CCNC has a preference toward regulating cell
cycle genes transcriptionally upregulated by SRC-2. Whether the inter-
action between SRC-2 and CCNC is exclusive compared to the other two
SRC family members needs to be further examined. However, in the
work presented here, we found an interaction between CCNC and the
SRC-2 degradation domain aa 347-758, the latter not identiﬁed in the
other two SRC proteins. This may suggest that, if there is an interaction
between CCNC and any of the two other SRC family members, it may
result in a different functional outcome.
We found of particular interest modulations in two central signaling
hubs - Myb and MCM7 (Mini chromosome maintenance 7). Myb is a
general cell cycle regulator, involved in cell survival, EMT and invasion
of breast cancer [46–48].MCM7, as part of theMCM complex, speciﬁcal-
ly promotes G1/S transition by stimulating DNA replication and is
known to be directly upregulated byMyb and SRC-3 [49–51]. Addition-
ally, the MCM7 gene is a host for a cluster of intronic miRNAs, which
inhibit tumor suppressors such as pTEN, p21, E2F1 and BIM, involving
MCM7 in cancer initiation and regulation of apoptosis [50]. This
miR106b cluster is directly stimulated by CDK6 [52], cyclin-dependent
kinase, which is regulated by both SRC-2 and CCNC. CDK6 is known to
negatively regulate cell differentiation and, in conjunction with cyclins
D 1-3, phosphorylates RB1 and promotes G1/S transition [53,54].
Aside from KIF5C, a mitotic microtubule kinesin-like protein,
SRC-2 and CCNC depletions signiﬁcantly affect gene expression of
Retinoblastoma binding protein 8 (RBBP8). Most notably known for its
interaction with BRCA1 and involvement in DNA damage response,
Fig. 7. CCNC affects the dynamics of SRC-2 degradation. COS-1 cells were co-transfected for overexpression of HA-SRC-2 and simultaneous silencing of endogenous CCNC. After 24 h, cells
were depletedofmethionine for 1 h, then pulse-labeled in [35S]-Methionine for another hour and chased for radioactive signal inmethionine-richmedium0, 6, 8, 10, 20 and24h (Aand B),
and 0, 1.5, 3 and 6 h (C and D) after the pulse. (A and C) HA-SRC-2 was immunoprecipitated using anti-GRIP1 antibody. IP samples were resolved on an SDS-PA gel and, together with
inputs, detected by autoradiography. Total protein was detected by Coomassie staining. (B and D) Radioactive signal was quantiﬁed in MultiGauge (Fuji) program. Results represent
mean of three (B; ± SD) and two (D) independent experiments, normalized to time point 0 h. Statistical signiﬁcance was calculated using the Student t-test (** p ≤ 0.01).
2389O. Bozickovic et al. / Biochimica et Biophysica Acta 1853 (2015) 2383–2391RBBP8 is a DNA endonuclease and a transcriptional coregulator,
generally considered to be a tumor suppressor [55,56]. Further, Bcl-2,
an anti-apoptotic factor and chemoresistance marker, has previously
been reported to be repressed by SRC-3 depletion in an ERα- and E2-
dependent manner, whereas SRC-2 depletion had no effect on Bcl-2
expression in MCF-7 cells [10]. This is in contrast to our ﬁndings,
where we detected Bcl-2 reduction by both stable SRC-2 knockdown
[12] and transient CCNC depletion.
We have previously reported that the SRC-2 domain aa 347-758 is
involved in the degradation of SRC-2 [17]. Here we report that theFig. 8. CCNC regulates expression of cell cycle genes targeted by SRC-2. Gene expression
analysis of cell cycle genes previously shown to be downregulated by stable SRC-2 knock-
down in MCF-7 cells [12]. MCF-7 cells were treated with 100 nM of either control siRNA
(NSC) or a combination of two CCNC-speciﬁc siRNAs. Samples were harvested 48 h after
transfection for gene expression analysis by RT-qPCR. Data are presented as mean ± SD
(* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).minimum binding CCNC element interacting with this domain is the
N-terminal domain up to helix 3 (H3) of Cyclin repeat 1. More precisely,
helices HN and H1–H3 were sufﬁcient for CCNC to bind to SRC-2 in a
yeast two-hybrid assay. Despite the fact that HN–H2 and partly H3 are
deleted in shorter CCNC isoform b, we were able to detect interaction
between this CCNC isoform and full-length SRC-2 in vitro. This suggests
that H3 is an important element of CCNC binding to SRC-2. Based on
structural prediction of CCNC, the highly conserved helix H3 forms
direct contact with CDK8 and is involved in maintaining active confor-
mation of the latter [35]. Additionally, due to its ﬂexibility, the entire
CCNC N-terminal domain is predicted to interact with and change its
position upon interaction with MED12 and MED13, the remaining two
members of CDK transcription module, and possibly other proteins,
such as SRC-2, as part of the Mediator complex [35].Fig. 9. Expression of cell cycle genes upregulated by SRC-2 silencing is not affected by
CCNC knockdown. Gene expression analysis of cell cycle genes previously shown to be up-
regulated by SRC-2 knockdown inMCF-7 cells [12]. MCF-7 cells were treatedwith 100 nM
of either control siRNA (NSC) or a combination of twoCCNC-speciﬁc siRNAs. Sampleswere
harvested 48 h after transfection for gene expression analysis by RT-qPCR. Data are pre-
sented as mean ± SD (** p ≤ 0.01).
2390 O. Bozickovic et al. / Biochimica et Biophysica Acta 1853 (2015) 2383–2391In summary, our data introduce a new regulation of SRC-2 through
direct interaction with a regulator of the cell cycle, CCNC. Analyses
suggested that CCNC stabilizes SRC-2 protein level, whereas translation
of mRNA remained unaffected. Finally, it seems that CCNC has a prefer-
ence toward regulating cell cycle gene stranscriptionally upregulated by
SRC-2.
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